Evidence map›Paper›PMID 41120147›Full record

ArticleBMJ open2025

Randomised, double-blind, placebo-controlled, parallel-group study to assess the efficacy and safety of antibiotic faecal microbiota transplantation in patients with Parkinson's disease (FLORA-PD): a study protocol.

Haruka Takeshige-Amano, Eriko Igami, Ayami Okuzumi, Ryota Kamo, Mariko Iseki, Kou Tsuyama, Ryo Wakamori, Hanna Okada, Daisuke Taniguchi, Shin-Ichi Ueno and 15 more

Abstract readClinical Trial Protocol
In one paragraph

Article in BMJ open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Haruka Takeshige-AmanoDepartment of Neurology, Juntendo University Faculty of Medicine, Tokyo, Japan thatano@juntendo.ac.jp h-amano@juntendo.ac.jp.ORCID http://orcid.org/0000-0003-3326-8559
Eriko IgamiDepartment of Neurology, Juntendo University Faculty of Medicine, Tokyo, Japan.
Ayami OkuzumiDepartment of Neurology, Juntendo University Faculty of Medicine, Tokyo, Japan.
Ryota KamoDepartment of Neurology, Juntendo University Faculty of Medicine, Tokyo, Japan.
Mariko IsekiDepartment of Neurology, Juntendo University Faculty of Medicine, Tokyo, Japan.
Kou TsuyamaDepartment of Neurology, Juntendo University Faculty of Medicine, Tokyo, Japan.
Ryo WakamoriDepartment of Neurology, Juntendo University Faculty of Medicine, Tokyo, Japan.
Hanna OkadaDepartment of Neurology, Juntendo University Faculty of Medicine, Tokyo, Japan.
Daisuke TaniguchiDepartment of Neurology, Juntendo University Faculty of Medicine, Tokyo, Japan.
Shin-Ichi UenoDepartment of Neurology, Juntendo University Faculty of Medicine, Tokyo, Japan.
Yutaka OjiDepartment of Neurology, Juntendo University Faculty of Medicine, Tokyo, Japan.
Kei-Ichi IshikawaDepartment of Neurology, Juntendo University Faculty of Medicine, Tokyo, Japan.
Noriko NishikawaDepartment of Neurology, Juntendo University Faculty of Medicine, Tokyo, Japan.
Masayuki OrikasaDepartment of Gastroenterology, Juntendo University Faculty of Medicine, Tokyo, Japan.
Rina OdakuraDepartment of Gastroenterology, Juntendo University Faculty of Medicine, Tokyo, Japan.
Masao KomaDepartment of Gastroenterology, Juntendo University Faculty of Medicine, Tokyo, Japan.
Takafumi MaruyamaDepartment of Gastroenterology, Juntendo University Faculty of Medicine, Tokyo, Japan.
Kei NomuraDepartment of Gastroenterology, Juntendo University Faculty of Medicine, Tokyo, Japan.
Dai IshikawaDepartment of Gastroenterology, Juntendo University Faculty of Medicine, Tokyo, Japan.
Tomoyoshi ShibuyaDepartment of Gastroenterology, Juntendo University Faculty of Medicine, Tokyo, Japan.
Akihito NagaharaDepartment of Gastroenterology, Juntendo University Faculty of Medicine, Tokyo, Japan.
Hideyuki TeramotoMetagen Therapeutics Inc, Tsuruoka, Japan.
Naotake YanagisawaMedical Technology Innovation Center, Juntendo University, Tokyo, Japan.
Taku HatanoDepartment of Neurology, Juntendo University Faculty of Medicine, Tokyo, Japan thatano@juntendo.ac.jp h-amano@juntendo.ac.jp.ORCID http://orcid.org/0000-0002-6808-0444
Nobutaka HattoriDepartment of Neurology, Juntendo University Faculty of Medicine, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe intestinal microbiota of people with Parkinson's disease (PwP) differs significantly from that of healthy individuals. Given that altered microbiota may play a role in the pathogenesis of Parkinson's disease, faecal microbiota transplantation (FMT) has been proposed as a potential therapeutic approach. However, the efficacy of FMT in improving motor symptoms in PwP has been inconclusive in some pilot randomised controlled trials (RCT). Previous RCTs on PwP employed simple FMT, but our modified approach-pretreatment with antibiotics before FMT (A-FMT)-has been shown to improve the engraftment rate of given species and the beneficial effects of FMT. This study aims to evaluate the efficacy and safety of A-FMT for PwP, particularly in those with motor fluctuations. METHODS AND ANALYSIS: This study is a randomised, double-blind, placebo-controlled, parallel-group study with an 8-week observation period following a single A-FMT. Thirty clinically established PwP with prominent motor fluctuation episodes will be randomised 1:1 to FMT or placebo. Participants in both groups will receive antibiotic treatment prior to colonoscopy for FMT or placebo treatment. Primary and secondary endpoints will include subjective and objective evaluations of motor and non-motor symptoms and will be evaluated before and after antibiotic treatment and at 4 and 8 weeks after the procedure. Exploratory endpoints will include blood and faecal sample analyses, advanced brain MRI and pharmacokinetic assessment of levodopa concentrations during a levodopa challenge test. ETHICS AND DISSEMINATION: This study has been approved by the ethical committee of Juntendo University in August 2024 (J24-005) and will be conducted in accordance with the Declaration of Helsinki, the Japan Ministry of Health, Labour and Welfare Clinical Trials Act and related laws and regulations. All patient data will be anonymised to protect privacy and used solely for study purposes. Results will be published in academic journals and presented at conferences. TRIAL REGISTRATION NUMBER: jRCTs031240344.

Indexed as

Anti-Bacterial AgentsFecal Microbiota TransplantationGastrointestinal MicrobiomeParkinson DiseaseDouble-Blind MethodFemaleHumansMaleMiddle AgedRandomized Controlled Trials as TopicTreatment OutcomeAnti-Bacterial AgentsAntibioticsClinical trialsMicrobiotaNEUROLOGYParkinson-s disease

Identifiers

PMID41120147
PMCPMC12548586

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.